![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Parand Darou Pharma](https://www.pharmacompass.com/image/flap/parand-darou-desktop-headergif-12950.gif)
![Parand Darou Pharma](https://www.pharmacompass.com/image/flap/parand-darou-mobgif-20656.gif)
Active Filter(s):
Details:
ATR-258 binds to the beta-2-adrenoceptor, initiating a process that mediates the transportation of glucose into skeletal muscle, lowering blood glucose levels and positively affecting several organs affected by Type 2 diabetes.
Lead Product(s): ATR-258
Therapeutic Area: Endocrinology Product Name: ATR-258
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024